Healthpeak Properties earnings release, August 4, 2026

Healthpeak Properties, Inc. (DOC) · Form 8-K, Item 2.02 · Filed · SEC filing

Healthpeak Properties Reports Second Quarter 2026 Results and Increases Full Year 2026 Earnings Guidance

DENVER, August 4, 2026 -

Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended June 30, 2026.

SECOND QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.08 per share and FFO as Adjusted of $0.46 per share – Second quarter Outpatient Medical and Lab new and renewal lease executions totaled 1.6 million square feet:

• Outpatient Medical new lease executions totaled 327,000 square feet and renewal lease executions totaled 916,000 square feet

◦ Subsequent to the second quarter, we have entered into approximately 204,000 square feet of Outpatient Medical leases and have another approximately 882,000 under signed letters of intent ("LOIs")

• Lab new lease executions totaled 222,000 square feet and renewal lease executions totaled 159,000 square feet

◦ Subsequent to the second quarter, we have entered into approximately 20,000 square feet of Lab leases and have another approximately 480,000 square feet under signed LOIs – Total occupancy increased sequentially by +20 basis points ("bps") in Outpatient Medical to 90.7% and by +80 bps in Lab to 78.5% – Janus Living (NYSE: JAN) reported year-over-year revenue and Adjusted EBITDAre growth of 45% and 34%, respectively – Entered into a new $20 million outpatient medical development agreement to support Northside Hospital’s continued expansion in the Atlanta market – Generated $1.4 billion of proceeds from Outpatient Medical recapitalizations, seller financing loan repayments, and dispositions during the second quarter and through August 3, bringing year-to-date proceeds to $1.75 billion

• As previously disclosed, in July 2026, closed on the recapitalization and sale of a 49% joint venture interest in an 86-asset, 5.6 million square foot outpatient medical portfolio to affiliates of Brookfield at a gross valuation of $2.1 billion, generating proceeds of approximately $1.025 billion – Net Debt to Adjusted EBITDAre was 4.7x for the quarter ended June 30, 2026 – Authorized new $500 million share repurchase program – Published 15 th annual Corporate Impact Report highlighting Healthpeak's continued focus on building a resilient portfolio, advancing sustainability goals, fostering a workplace culture guided by our WE CARE core values, and promoting sound corporate governance and transparency

To learn more and view the Corporate Impact Report, please visit www.healthpeak.com/corporate-impact

SECOND QUARTER RESULTS

Page 1

Page 2

JANUS LIVING SECOND QUARTER FINANCIAL AND OPERATING HIGHLIGHTS

• Revenue of $216 million, up 45% compared to the prior year quarter

• Adjusted EBITDAre of $79 million, up 34% compared to the prior year quarter

• Total Adjusted Net Operating Income of $58 million, up 37% compared to the prior year quarter

◦ Same-store Adjusted NOI increased 19.2% and margin expanded 250 basis points

• During the second quarter, acquired two senior housing communities for approximately $105 million

• Subsequent to quarter end, and through August 3, 2026, completed approximately $1.0 billion of senior housing acquisitions

• As of August 3, 2026, and subsequent to closing the acquisitions referenced above, Janus Living had approximately $558 million of unrestricted cash and no outstanding debt

• Under purchase agreement for approximately $59 million incremental senior housing acquisition

Janus Living, Inc. is a pure-play senior housing real estate investment trust that owns high-quality communities across the United States, and is majority owned by Healthpeak. Healthpeak owns 214.7 million shares of Janus Living common stock and operating partnership common units, representing a 73.6% equity ownership as of June 30, 2026. Janus Living is consolidated into Healthpeak’s financial statements, with the approximately 26.4% not owned by Healthpeak reported as noncontrolling interest.

NORTHSIDE OUTPATIENT MEDICAL DEVELOPMENT

In June 2026, Healthpeak entered into a development agreement for a new $20 million, 33,000 square foot outpatient medical building in the Sugar Hill submarket of Atlanta, Georgia.

The development is 84% pre-leased to Northside Hospital and affiliated physician groups supporting a range of clinical services and extends Northside’s network in a high-growth submarket connecting its Forsyth and Gwinnett hospital campuses.

The development represents Healthpeak’s fifth ground-up project totaling 565,000 square feet supporting Northside Hospital’s continued outpatient expansion in the Atlanta market.

OUTPATIENT MEDICAL JOINT VENTURE RECAPITALIZATION

As previously disclosed, in July 2026, Healthpeak entered into a joint venture with affiliates of Brookfield Asset Management (“Brookfield”) through the contribution of an 86-property outpatient medical portfolio valued at approximately $2.1 billion. The portfolio comprises approximately 5.6 million square feet and is located across 11 states including Kentucky, Indiana, Pennsylvania, Arkansas, Illinois, Minnesota, New Jersey, and New York. The portfolio is 95% leased with a weighted average remaining lease term of six years.

Under the terms of the joint venture, Brookfield owns a 49% non-controlling equity interest and Healthpeak retains a 51% interest in the joint venture and serves as managing member, providing asset and property management services and earning customary fees.... (truncated)return excluding initial transaction expenses.

The joint venture advances Healthpeak’s capital allocation strategy by generating proceeds to strengthen its balance sheet, fund investment opportunities, and support long-term growth. The transaction establishes a structure by which the parties can expand their relationship over time and also underscores the differentiated platform Healthpeak has built, including deep health system relationships and ongoing investments across the enterprise in technology, systems, and innovation that enhance long-term portfolio performance.

SELLER FINANCING LOAN REPAYMENT AND OTHER DISPOSITIONS

In June 2026, Healthpeak received approximately $400 million of gross proceeds from the partial repayment of a seller financing loan. The remaining $20 million loan balance was extended by 12 months pursuant to contractual extension rights. The repayment resulted in a one-time $9 million increase in interest income from the accelerated recognition of the remaining fair value discount.

During the second quarter of 2026, Healthpeak closed on $40 million of non-core outpatient medical dispositions at

Page 3 a trailing cash capitalization rate of 4.9%.

Financial statements

Income Statement

Three Months Ended June 30, — In thousands, except per share data

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues:Rental and related revenues533,354529,6871,071,7901,067,828
Revenues:Resident fees and services216,456148,855416,801297,782
Revenues:Interest income and other21,76915,80635,94031,627
Revenues:Total revenues771,579694,3481,524,5311,397,237
Costs and expenses:Operating333,123276,181656,984549,324
Costs and expenses:Depreciation and amortization283,390265,916573,124534,462
Costs and expenses:Interest expense92,28075,063179,572147,756
Costs and expenses:General and administrative22,51720,76447,10846,882
Costs and expenses:Transaction costs9,17210,21533,32115,749
Costs and expenses:Impairments and loan loss reserves (recoveries), net-1,4793,499-3,754-63
Costs and expenses:Total costs and expenses739,003651,6381,486,3551,294,110
Other income (expense):Gain (loss) on sales of real estate, net9,9881,63660,6571,636
Other income (expense):Gain (loss) on debt extinguishments-403
Other income (expense):Other income (expense), net16,766-4,692156,545-10,818
Other income (expense):Total other income (expense), net26,754-3,056216,799-9,182
Other income (expense):Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures59,33039,654254,97593,945
Other income (expense):Income tax benefit (expense)1,402-2,3821,148-4,462
Other income (expense):Equity income (loss) from unconsolidated joint ventures2,5091,7476,774-400
Other income (expense):Net income (loss)63,24139,019262,89789,083
Other income (expense):Noncontrolling interests’ share in earnings-10,423-7,346-16,446-14,582
Other income (expense):Net income (loss) attributable to Healthpeak Properties, Inc.52,81831,673246,45174,501
Other income (expense):Participating securities’ share in earnings-150-115-299-579
Other income (expense):Net income (loss) applicable to common shares52,66831,558246,15273,922
Earnings per common share:Basic0.080.050.360.11
Earnings per common share:Diluted0.080.050.360.11
Weighted average shares outstanding:Basic689,885695,188692,508697,117
Weighted average shares outstanding:Diluted689,885695,194692,843697,146

Income Statement

Three Months Ended June 30, — In thousands, except per share data

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss) applicable to common shares52,66831,558246,15273,922
Real estate related depreciation and amortization283,390265,916573,124534,462
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures7,64412,53014,85624,730
Noncontrolling interests’ share of real estate related depreciation and amortization-15,421-4,426-20,123-8,879
Loss (gain) on sales of depreciable real estate, net-9,988-1,636-60,657-1,636
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures1,7931,793
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net973973
Loss (gain) upon change of control, net(1)-226-138,343
Taxes associated with real estate dispositions-1,863-335-1,805-335
Nareit FFO applicable to common shares318,970303,607615,970622,264
Distributions on dilutive convertible units and other4,3844,5608,9309,183
Diluted Nareit FFO applicable to common shares323,354308,167624,900631,447
Diluted Nareit FFO per common share0.460.430.880.89
Weighted average shares outstanding - Diluted Nareit FFO704,472709,839707,066711,828
Impact of adjustments to Nareit FFO:Transaction, merger, and restructuring-related costs(2)7,73410,21528,30215,749
Impact of adjustments to Nareit FFO:Other impairments (recoveries) and other losses (gains), net(3)-1,4793,499-3,754179
Impact of adjustments to Nareit FFO:Loss (gain) on debt extinguishments302
Impact of adjustments to Nareit FFO:Casualty-related charges (recoveries), net(4)-4,1913,919-4,3818,145
Impact of adjustments to Nareit FFO:Recognition (reversal) of valuation allowance on deferred tax assets(5)-3,058
Impact of adjustments to Nareit FFO:Total adjustments2,06417,63317,41124,073
Impact of adjustments to Nareit FFO:FFO as Adjusted applicable to common shares321,034321,240633,381646,337
Impact of adjustments to Nareit FFO:Distributions on dilutive convertible units and other4,3824,5458,9169,161
Impact of adjustments to Nareit FFO:Diluted FFO as Adjusted applicable to common shares325,416325,785642,297655,498
Impact of adjustments to Nareit FFO:Diluted FFO as Adjusted per common share0.460.460.910.92
Impact of adjustments to Nareit FFO:Weighted average shares outstanding - Diluted FFO as Adjusted704,472709,839707,066711,828
Other operating data:Amortization of deferred financing costs and debt discounts (premiums)8,9007,87517,26415,727
Other operating data:Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization12,86619,04220,62123,739
Other operating data:Stock-based compensation amortization expense4,3511,7388,8536,365

Balance Sheet

In thousands, except share and per share data

June 30, 2026December 31, 2025
Real estate:Buildings and improvements17,211,53616,593,535
Real estate:Development costs and construction in progress969,4951,010,657
Real estate:Land and improvements3,225,9573,007,346
Real estate:Accumulated depreciation-4,543,382-4,512,443
Real estate:Net real estate16,863,60616,099,095
Real estate:Loans receivable, net of reserves of $8,165 and $11,345261,398606,020
Real estate:Investments in unconsolidated joint ventures526,780802,601
Real estate:Accounts receivable, net of allowance of $3,523 and $2,01872,13478,327
Real estate:Cash and cash equivalents1,626,827467,457
Real estate:Restricted cash91,85870,245
Real estate:Intangible assets717,494654,516
Real estate:Assets held for sale37,10180,621
Real estate:Right-of-use asset395,124412,198
Real estate:Deferred tax assets122,320111,248
Real estate:Goodwill68,52968,529
Real estate:Other assets896,875885,161
Real estate:Total assets21,680,04620,336,018
Liabilities and EquityBank line of credit and commercial paper1,495,9941,078,850
Liabilities and EquityTerm loans1,646,2821,647,113
Liabilities and EquitySenior unsecured notes6,785,6976,772,722
Liabilities and EquityMortgage debt104,213349,209
Liabilities and EquityIntangible liabilities155,466173,697
Liabilities and EquityLiabilities related to assets held for sale59411,900
Liabilities and EquityLease liability288,194296,260
Liabilities and EquityAccounts payable, accrued liabilities, and other liabilities678,687718,509
Liabilities and EquityDeferred revenue1,026,479985,307
Liabilities and EquityTotal liabilities12,181,60612,033,567
Commitments and contingenciesRedeemable noncontrolling interests27,695159,581
Commitments and contingenciesCommon stock, $1.00 par value: 1,500,000,000 shares authorized; 689,465,312 and 695,036,731 shares issued and outstanding689,465695,037
Commitments and contingenciesAdditional paid-in capital13,273,88012,767,914
Commitments and contingenciesCumulative dividends in excess of earnings-6,129,129-5,952,920
Commitments and contingenciesAccumulated other comprehensive income (loss)10,534-9,937
Commitments and contingenciesTotal stockholders’ equity7,844,7507,500,094
Commitments and contingenciesPublic investors of Janus Living, Inc.979,186
Commitments and contingenciesJoint venture partners291,294295,455
Commitments and contingenciesNon-managing member unitholders355,515347,321
Commitments and contingenciesTotal noncontrolling interests1,625,995642,776
Commitments and contingenciesTotal equity9,470,7458,142,870
Commitments and contingenciesTotal liabilities and equity21,680,04620,336,018

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.